Orpyx®

At Orpyx®, we are on a mission to change the standard of care for foot ulcer and amputation prevention in diabetes, and we’re looking for a Director of Nursing to play a key role in shaping this transformative journey. We’re seeking an exceptional candidate with expertise in Quality Improvement (QI) and Health Systems Improvement (HSI), a strong background in clinical process optimization, and a deep passion for patient-centered care. You’ll lead the growing remote patient monitoring (RPM) nursing team and drive initiatives that focus on scalability, data-driven decision-making, and the seamless integration of remote care workflows—the care of the future, delivered right at home. If you're passionate about nursing leadership and ready to make a real impact on the lives of those who need it most, we would love to have you join our team. https://lnkd.in/gF_Q3-Rt

We’re looking for an exceptional IT Manager to join Orpyx. This position is an on-site role based out of Calgary, AB. https://lnkd.in/g4bhVQkh

From all of us at Orpyx, we hope you have a happy holiday season and a fantastic New Year!

As we gear up for #LSIUSA25 we’re showcasing the innovators from around the globe who are selected to present in Dana Point, California. Today we’re showcasing: 1. Denis Dufrane — NOVADIP Biosciences S.A. Biosciences → Clinical-stage company developing breakthrough stem cell-based tissue regeneration therapies to accelerate healing of large bone defects, bone non-union, and spine fusion in a single treatment. Novadip’s proprietary and patented 3M3 platform is a three-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly specific growth factors and miRNAs to mimic the physiology of the natural tissue healing. 2. Breanne Everett MD MBA — Orpyx® → The Orpyx® Sensory Insole system enhances standard custom orthotics with advanced multi-modal sensor technology for continuous remote monitoring, supported by a team of specialized nurses. The system tracks critical parameters like plantar pressure, temperature, activity, and adherence, essential for preventing debilitating foot complications in individuals with diabetes and neuropathy. By supporting effective foot and limb management, Orpyx aims to reduce wounds and amputations, an area that drives one-third of the direct cost of diabetes. 3. Gabor Heltovics — SERDA therapeutics → A clinical-stage biopharmaceutical company developing a groundbreaking prescription product for fast and effective wound debridement. Utilizing a proprietary proteolytic enzyme, the therapy selectively digests necrotic tissue and eschar, paving the way for wound healing while minimizing irritation. Targeting burn wounds and chronic ulcers such as diabetic foot and venous leg ulcers, SERDA’s solution addresses the challenges of current debridement methods, which are often costly, ineffective, and painful. We look forward to seeing these innovators take the stage March 17th - 21st in Dana Point. Want to see what other innovators are presenting at LSI USA ‘25? Head over to our website to see the 200+ innovators selected to present. Interested in presenting at the event? Apply to present on our website today while space is still available.

What is the value of personalized care? How do we incorporate population baseline thresholds and personal temperature thresholds into our interface so that our nurses are able to triage patients and reduce false negatives? This blog post by Emily Bray provides an excellent introduction to our new Personal Baseline Asymmetry Algorithm. https://hubs.ly/Q02-BC4d0 Additional thanks to Maryam Hajizadeh, Emily Matijevich, and Evan Minty to their contributions to our new white paper.

🌟 Exciting strides in personalized medicine 🌟 Thrilled to share our latest white paper on personalized plantar temperature monitoring - a significant step forward in advancing care for individuals with diabetes at risk for foot complications Why is this a game-changer? 👣 Fixed population thresholds don’t work for everyone. Personalized care embraces the unique circumstances of each patient. 👣 By focusing on individualized data, clinicians are empowered to develop more meaningful engagements and care plans to match a patients unique and dynamically changing risk level 👣 Personlized, remote care solutions have the power to reduce unnecessary clinical escalations, easing the burden on both patients and the healthcare system. Personalized care starts with personalized data.

At Orpyx, our technology is backed by people that are passionate about making a difference in the lives of those living with diabetes. Dr. Emily Matijevich, Director of Biometrics and Applied Research at Orpyx, has led a project to develop the first personalized baseline plantar temperature algorithm that highlights the importance of using personalized data analytics that are specific to the individual. The full white paper, Personalized plantar temperature monitoring for DFU risk reduction, is available here: https://hubs.ly/Q02Zz-1N0 Thanks to coauthors Maryam Hajizadeh, Emily Bray, and Evan Minty.

One step, one heartbeat at a time. At Relentless we are guided by our core values: Service, Impact, Excellence, Curiosity, Integrity, Hope, Equity, and Diversity. Today’s heart rhythm is set by reflecting on the Relentless team value of EXCELLENCE. We are in the relentless pursuit of innovation. Our investments are catalysts for positive transformation in the health technology sector. Part of the transformation in health is an individual’s ability to manage their health in ways previously out of reach. As we come to the end of #DiabetesAwareness Month, Breanne Everett MD MBA shares why the development of the Orpyx® remote patient monitoring solution is an essential piece to an evolved healthcare system. #RelentlessPulse #diabetes #chronicdiseasemanagement #RPM #remotepatientmonitoring #healthtech #medtech #impactinvesting Relentless Venture Fund

🚨 NEW WHITE PAPER ALERT 🚨 “Personalized plantar temperature monitoring for diabetic foot ulcer risk reduction” Maryam Hajizadeh Emily Bray Evan Minty 🦶 BACKGROUND Remote plantar temperature monitoring is an evidence-based strategy for identifying plantar “hot spots” (inflammation). Early detection enables treating pre-ulcerative wounds before they escalate to more serious complications (ulcer, infection, amputation). 🌡️ CLINICAL GAP Current clinical guidelines offer a single population threshold for identifying a temperature trend of concern: left/right asymmetries >2.2°C. However, some common co-morbidities (think peripheral arterial disease) also cause limb temperature asymmetries. These individuals may be at risk of under/over alerting with current temperature monitoring protocols. 📈 NEW DEVELOPMENT The Orpyx® Sensory Insole program now features a “baseline temperature asymmetry” algorithm. The algorithm identifies users with an underlying baseline temperature asymmetry, and adjusts the thresholds to monitor for deviations from this personal baseline. 🩺 BROADER IMPACT Any screening tool must balance the risk of not offering treatment to people who would develop an ulcer (“false negative” alert) against treating people who would not develop an ulcer (“false positive” alert). Personalized medicine aims to narrow this gap by accounting for inter-individual variations in disease progression. 💙 The most meaningful clinical engagements start with the most personalized data. Read the white paper ➡️ https://lnkd.in/gVWn5sqU

November is Diabetes Awareness Month, and we’re sharing our new white paper, Personalized Plantar Temperature Monitoring for DFU Risk Reduction, to highlight how important it is to view people living with diabetes as an individual, rather than as a statistic. Personalized care can make a huge impact. Click here to for access to the white paper. https://hubs.ly/Q02ZdTv_0